培美曲赛联合顺铂二线治疗晚期肺腺癌临床分析

目的 探讨培美曲赛联合顺铂方案治疗一线吉非替尼治疗失败的晚期肺腺癌的临床疗效和毒性.方法 对2009年1月至2010年6月本院60例一线应用吉非替尼与卡铂/紫杉醇(CP方案)化疗失败的晚期肺腺癌患者使用培美曲赛联合顺铂方案化疗.化疗方法:培美曲赛500 mg/m2加入生理盐水(0.9%氯化钠注射液)100ml静脉点滴;...

Clinical observation of pemetrexed combined cisplaton as second-line treatment for advanced lung adenocarcinoma

Objective To explore the efficacy and toxicity of pemetrexed combined Cisplaton AS second-line treatment for advanced lung adenocarcinoma.Methods 60 cases with end-stage lung adenocarcinoma who were failed treatment for nehemiah and carboplatin/taxol(CP) chemotherapy were used pemetrexed combined cisplaton AS chemotherapy from January 2009 to June 2010 in our hospital.100 ml of pemetrexed 500 mg/m2 joining 0.9% of sodium chloride were for intravenous injection,cisplatin 75 mg/m2,repeat one time each 3 weeks,completed two cycles about above chemotherapy and evaluated the clinical and toxicity.Results 1) Complete remission(CR) was 0 case,partial remission(PR) were 4 cases,stable(SD) were 35 cases and progress(PD) were 11 cases in 60 patients;the total effective was 6.7%(4/60),the rates of disease control(DCR) was 65.0%(39/60).(2) Toxicity is mainly exhaustion of 33 cases(55.0%),leukocyte fell were 26 cases(43.3%),degrees decline were 4 cases(6.7%),gastrointestinal reaction were 19 cases(31.7%),allergic reactions were 2 cases(3.3%),it did not affect chemotherapy after symptomatic treatment.Conclusion Pemetrexed combined Cisplaton AS second-line treatment for advanced lung adenocarcinoma is one of the ideal solutions.